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Abstract: Clear cell renal carcinoma (ccRCC) is frequently associated with cachexia which is itself
associated with decreased survival and quality of life. We examined relationships among body
phenotype, tumor gene expression, and survival. Demographic, clinical, computed tomography (CT)
scans and tumor RNASeq for 217 ccRCC patients were acquired from the Cancer Imaging Archive
and The Cancer Genome Atlas (TCGA). Skeletal muscle and fat masses measured from CT scans and
tumor cytokine gene expression were compared with survival by univariate and multivariate analysis.
Patients in the lowest skeletal muscle mass (SKM) quartile had significantly shorter overall survival
versus the top three SKM quartiles. Patients who fell into the lowest quartiles for visceral adipose
mass (VAT) and subcutaneous adipose mass (SCAT) also demonstrated significantly shorter overall
survival. Multiple tumor cytokines correlated with mortality, most strongly interleukin-6 (IL-6);
high IL-6 expression was associated with significantly decreased survival. The combination of low
SKM/high IL-6 was associated with significantly lower overall survival compared to high SKM/low
IL-6 expression (26.1 months vs. not reached; p < 0.001) and an increased risk of mortality (HR = 5.95;
95% CI = 2.86–12.38). In conclusion, tumor cytokine expression, body composition, and survival are
closely related, with low SKM/high IL-6 expression portending worse prognosis in ccRCC.
Keywords: cachexia; body composition; kidney cancer; renal cancer; renal cell carcinoma; cytokines;
body composition; muscle wasting; mortality; prognosis; risk stratification
1. Introduction
Renal Cell Carcinoma is the third most common cancer of the genitourinary tract [1] and its
incidence is increasing in the United States [2]. The clear cell variant of Renal Cell Carcinoma (ccRCC)
represents over 80% of all histologic subtypes of renal cancer [3], and is frequently associated with the
development cachexia symptoms [4–6]. Cachexia, a complex metabolic derangement characterized by
skeletal muscle and fat loss develops in a significant number of patients with ccRCC. Previous studies
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have shown that development of cachexia is associated with a three-fold increased rate of disease
recurrence and a four-fold increased risk of disease specific death in patients with ccRCC [7].
Cachexia, which affects up to 80% of patients with advanced cancer [8], is also associated with
decreased quality of life, poor response to chemotherapy, and has been implicated as the cause of death
as many as 20% of cancer patients [9–11]. Furthermore it has been established that the development
of cachexia symptoms is associated with a decreased overall survival [3,6,12,13], and poor outcomes
following surgery or targeted therapy for ccRCC [14–17]. Additionally, low muscle mass has been
shown to be a significant predictor of sorafenib toxicity in patients with metastatic renal carcinoma [18].
Cachexia is caused, in part, by the pleiotropic actions of inflammatory cytokines on multiple
tissues from modulating the tumor microenvironment, to disrupting hematopoiesis, to altering central
mechanisms of food intake, basal temperature, activity, and energy expenditure, to direct induction of
lipolysis, muscle catabolism and bone loss [19,20]. The collective action of cytokines result in impaired
host defenses and wasting of peripheral tissues, leading to reduced response to chemotherapy, high
rates of adverse events, progressive functional decline, and death. Cytokines implicated in these
disease processes, either through association in patient studies or via functional studies in animal
models include Tumor Necrosis Factor (TNF), interleukin-1α (IL-1α), interferon-gamma (INF-γ),
members of the Transforming Growth Factor-β (TGF-β) superfamily, including TGF-β itself as well
as the Activins, Myostatin, Growth Differentiation Factor-15 (GDF-15), GDF-11, and members of
the Interleukin-6/GP130 superfamily, including IL-6, Leukemia Inhibitor Factor (LIF), and ciliary
neurotrophic factor (CNTF) [21–23] Among these, TNF [24] and IL-6 [25] are the best studied, followed
by IL-1α [26], Activin [27], and TGF-β [28], with far less information about the other cytokines.
Consistent with a role for inflammatory cytokines in cachexia of patients with ccRCC, cytokines
and markers of the inflammatory response such as C-reactive protein, low albumin and high
neutrophil-to-lymphocyte ratio are also associated with poor outcomes in ccRCC. Serum concentrations
of TNF-∝, IL-6 and INF-γ are elevated in a subset of patients with ccRCC compared to healthy
controls [29]. Elevated serum L-6 has also been shown to be a negative prognostic factor in patients
with renal cell carcinoma [29,30] and to associate with weight loss and other paraneoplastic symptoms
in this disease [31]. Less studied is the association of tumor-expressed cytokines and the systemic
response to cancer.
This study uses a national database of patient CT scans, demographic information, tumor gene
expression data and disease specific data to assesses the association between skeletal muscle (SKM),
visceral adipose (VAT), and subcutaneous adipose (SCAT) mass and overall survival in patients with
ccRCC. Additionally, tumor-derived cachexia-associated cytokines were assessed for correlation with
skeletal muscle, fat, and overall survival. The results demonstrate, for the first time, a strong association
of low muscle mass and high tumor IL-6 expression with mortality, a finding that could eventually be
useful in treatment and prognostication in ccRCC.
2. Results
2.1. Patient Clinical Characteristics
The baseline patient characteristics were determined and are shown in Table 1. The overall mean
age was 59.65 years (SD = 12.46) with no significant difference between men and women. There was
no significant difference in tumor grade, American Joint Committee on Cancer (AJCC) stage, or tumor
laterality between men and women.
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Table 1. Patient Characteristics n = 217.
Variable No. (%) Male/Female p Value




Grade 1 0 (0) 0/0
Grade 2 87 (40) 48/39
Grade 3 94 (43) 69/25 0.123
Grade 4 36 (17) 22/14
AJCC Stage
Stage 1 112 (52) 71/41
Stage 2 18 (8) 17/1
Stage 3 54 (25) 34/20 0.459
Stage 4 33 (15) 17/16
Tumor Laterality
Right 116 (53) 78/38
0.295Left 101 (47) 61/40
Abbreviations: AJCC = American Joint Commission on Cancer.
2.2. Body Composition
The analysis of body composition by age showed patients below the median age had significantly
more SKM but no difference in VAT or SCAT when compared to those above the median (Table 2). The
lower stage was also associated with increased SKM, VAT and SCAT (Table 2).
Table 2. Body Composition/Tissue Area Measurements.
Variation Mean SKM, cm
2
(SD)
p Value Mean VAT, cm
2
(SD)




Overall 155.1 (41.3) 179.3 (109.9) 200.8 (93.3)
Top Quartile 192.3 (38.1) <0.001 310.0 (85.3) <0.001 326.6 (73.3) <0.001
Bottom Quartile 121.9 (28.6) <0.001 65.2 (41.8) <0.001 104.5 (27.0) <0.001
Age






≥59.7 years 140.1 (35.6) 181.2 (112.5) 195.5 (92.1)
AJCC Stage






Stage II 181.5 (37.6) 247.9 (143.4) 204.4 (75.3)
Stage III 149.4 (39.3) 165.2 (143.4) 197.3 (93.4)
Stage IV 133.7 (31.2) 116.0 (71.0) 166.2 (77.1)
Abbreviations: SKM = skeletal muscle mass, VAT = visceral adipose tissue mass, SCAT = subcutaneous adipose
tissue mass.
2.3. Characteristics Associated with Survival
The median overall survival (OS) for all patients was calculated using Kaplan–Meier analysis
methods and was 75.2 months. There was no sex-specific difference in overall survival, which was 75.6
months for males and 64.6 months for females (p = 0.123). The univariate analysis revealed that age
greater than median, lowest SKM, VAT and SCAT quartiles, AJCC stage 3/4, and left sided tumors were
associated with increased risk of mortality (Table 3). The Kaplan–Meier analysis showed the highest
three SKM quartiles had significantly longer overall survival than the bottom quartile (Figure 1A). This
was also true for IL-6 expression below the median (Figure 1B). The combination of low SKM/high IL-6
expression showed significantly worse overall survival than the combination of high SKM/low IL-6
expression (Figure 1C).
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Figure 1. Survival stratified by skeletal muscle and IL-6 expression. (A) Patients in the lowest skeletal
muscle mass quartile (blue line) had significantly shorter overall survival compared to the highest
quartile (red line), second highest quartile (yellow line) and third highest quartile (green line). (B)
Patients with IL-6 expression above the median (green line) have significantly shorter overall survival
compared to those with expression below the median (blue line). (C) The combination of low SKM/high
IL-6 expression (blue line) resulted in a decreased survival compared to high SKM/low IL-6 (red line),
high SKM/high IL-6 (yellow line) and low SKM/low IL-6 (green line). SKM, skeletal muscle.
Table 3. Association with All-Cause Mortality.
Univariate Analysis Multivariate Analysis







≥59.7 years 2.1 (1.3–3.6) 1.3 (0.7–2.6)
SKM mass
Top 3 quartiles Ref
<0.001
Ref
0.081Lowest quartile 3.2 (2.0–5.3) 1.8 (0.9–3.5)
VAT mass
Top 3 quartiles Ref
0.03
Ref
0.61Lowest quartile 1.8 (1.1–3.0) 1.2 (0.6–2.6)
SCAT mass
Top 3 quartiles Ref
<0.001
Ref















0.004Left 1.8 (1.1–2.9) 2.3 (1.3–4.2)
Sex
Male Ref 0.123
Not IncludedFemale 1.5 (0.9–2.3)
Abbreviations: SKM = skeletal muscle mass, VAT = visceral adipose tissue mass, SCAT = subcutaneous adipose
tissue mass, AJCC = American Joint Commission on Cancer.
2.4. Body Composition Versus Tumor Gene Expression
Body composition and tumor gene expression were analyzed for correlation, and the results are
shown in Table 4. SKM was found to have significant direct correlation with INHBB and TGFB2.
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VAT had a significant direct correlation with INHBB and inversely correlates with CCL2. SCAT was
found to have significant direct correlation with CNTF. Seven genes were found to be associated with
ACM and are summarized in Table 4. Of these seven genes, two were found to have a strong inverse
correlation with survival, IL-6 and IL-11. Others include INHA, OSM, IL1A, TGFB1, and CLCF1.
Table 4. Tumor Gene Expression and Associations with Body Composition and Overall Survival.











SCAT CNTF 0.167 0.027
Gene Correlation Coefficient Hazard Ratio p Value
IL6 0.835 2.31 <0.0001
IL11 0.700 2.01 <0.0001
INHA 0.622 1.86 0.0001
OSM 0.585 1.80 0.0004
IL1A 0.483 1.62 0.003
TGFB1 0.422 1.52 0.008
CLCF1 0.400 1.49 0.01
Abbreviations: SKM = skeletal muscle mass, VAT = visceral adipose tissue mass, SCAT = subcutaneous
adipose tissue mass, INHBB = Inhibin beta B, TGFB2 = Transforming Growth Factor β2, IL11 = Interluekin-11,
GDF11 = growth differentiation factor 11, CCL2 = C-C Motif Chemokine Ligand 2, CNTF = Ciliary Neurotrophic
Factor, IL6 = Interleukin 6. IL11 = Interleukin 11. INHA = Inhibin-α. OSM = Oncostatin M. IL1A = Interluekin 1a.
TGFB1 = Transforming Growth Factor β1. CLCF1 = Cardiotrophin-like Cytokine Factor 1.
2.5. Body Composition and Tumor Gene Expression Versus Survival
Patients were then stratified into groups based on SKM mass and expression of each cytokine
shown to have a significant association with survival. Of all possible combinations, low SKM/high IL-6
and low SKM/high CLCF1 demonstrated the lowest overall median survival at 26.1 months (Table 5).
The combination of low SKM/high IL-6 expression had the highest risk of mortality with HR = 5.95
(95%CI = 2.86–12.38) (Table 5).
Table 5. Skeletal Muscle Mass-Cytokine Expression Survival and Mortality Risk.
Group Median OS (Months) p Value Hazard Ratio 95% CI
SKM/IL6
High SKM/Low IL6 Not Defined a
<0.001
Reference
High SKM/High IL6 79.5 1.67 0.81–3.45
Low SKM/Low IL6 74.2 1.45 0.54–3.87
Low SKM/High IL6 26.1 5.95 2.86–12.38
SKM/INHA
High SKM/Low INHA Not Defined a
<0.001
Reference
High SKM/High INHA 70.2 1.82 0.88–3.77
Low SKM/Low INHA Not Defined a 3.17 1.24–8.10
Low SKM/High INHA 40.00 4.71 2.24–9.87
SKM/IL11
High SKM/Low IL11 Not Defined a
<0.001
Reference
High SKM/High IL11 Not Defined a 1.39 0.68–2.84
Low SKM/Low IL11 73.0 2.54 1.08–5.97
Low SKM/High IL11 40.0 4.71 2.24–9.94
SKM/OSM
High SKM/Low OSM Not Defined a
<0.001
Reference
High SKM/High OSM Not Defined a 0.83 0.41–1.67
Low SKM/Low OSM 79.5 1.45 0.57–3.71
Low SKM/High OSM 37.8 4.10 2.08–8.06
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Table 5. Cont.
Median OS (Months) p Value Hazard Ratio 95% CI
SKM/IL1A
High SKM/Low IL1A Not Defined a
0.001
Reference
High SKM/High IL1A Not Defined a 0.93 0.47–1.87
Low SKM/Low IL1A 75.2 2.40 0.99–5.85
Low SKM/High IL1A 43.9 2.84 1.42–5.68
SKM/TGFB1
High SKM/Low TGFB1 Not Defined a
<0.001
Reference
High SKM/High TGFB1 Not Defined a 1.31 0.65–2.66
Low SKM/Low TGFB1 41.0 3.95 1.74–8.93
Low SKM/High TGFB1 44.6 3.15 1.50–6.60
SKM/CLCF1
High SKM/Low CLCF1 Not Defined a
<0.001
Reference
High SKM/High CLCF1 Not Defined a 0.53 0.26–1.09
Low SKM/Low CLCF1 75.2 1.44 0.65–3.18
Low SKM/High CLCF1 26.1 3.44 1.74–6.82
Abbreviations: SKM—skeletal muscle mass; OS—overall survival; IL-6—interleukin-6; INHA—inhibin alpha;
IL-11—interleukin-11; OSM—oncostatin M; IL1A—interleukin 1 alpha; TGFB1 – tumor growth factor beta 1; CLCF1
—cardiotrophin like cytokine factor 1. a—median survival was not reached as greater than 50% of patients were still
alive at time of analysis.
3. Discussion
The current study evaluated the associations between body composition, tumor cytokine gene
expression and survival in patients with ccRCC. To the authors knowledge, this is the first study to
examine these relationships in ccRCC. The data show a clear relationship between body composition,
tumor cytokine expression, and survival in ccRCC. The most notable relationship is the association of
the combination of low SKM/high IL-6 expression and significantly decreased survival. These results
provide additional evidence of the interconnectivity of these factors and support their potential as
prognostic factors and possibly targets for intervention to improve outcomes.
Sarcopenia, defined as low skeletal muscle mass, is a well-established poor prognostic factor
for patients with malignancies including ccRCC [32]. One of the most widely used prognostic
models for ccRCC is the Memorial Sloan Kettering Cancer Center Renal Carcinoma Risk model
(MSKCC-RCC), which uses the Karnofsky performance scale as its measure of performance status.
This scale relies heavily on patient self-reporting and subjective physician observations, both of which
can be inconsistent. The incorporation of sarcopenia into the MSKCC-RCC model has been shown to
improve its predictive accuracy [32]. Unfortunately, the current study lacked all data points to calculate
the MSKCC-RCC score for patients. However, our data reinforce the importance of SKM and highlight
the importance of objective measures of SKM, perhaps even to fully replace subjective measures of
patient performance.
Obesity has also been shown to have prognostic value in renal cell carcinoma as it has been shown
to be associated with increased survival in patients with both localized and metastatic ccRCC [33,34].
While the reason for this survival advantage is unclear, the current study reinforces the notion that
fat has a protective role in ccRCC. Obesity, however, is also a known risk factor for developing RCC,
specifically the clear cell variant [35,36]. This paradox may be explained by how the fat is distributed
in the body, and not just its general presence.
Fat is no longer considered an inert tissue. Adipose tissue has been shown to produce multiple
inflammatory cytokines including IL-6 [37,38], and in particular, visceral adipose tissue has been shown
to produce IL-6 at greater levels than subcutaneous adipose tissue [39,40]. Elevated IL-6 levels have
also been shown to be associated with increased invasiveness and decreased survival in other cancers,
especially colon cancer [41,42]. Not only is IL-6 frequently elevated in renal cell carcinoma [31], Table 4
shows its expression is associated with a 2.3 times increased risk of mortality. No previous studies have
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examined the correlations between fat compartment distribution and the risk of developing ccRCC,
however with the data presented in the current study showing higher levels of SCAT to be protective
while higher levels of VAT show no advantage, it is possible that the culprit behind the increased risk
of ccRCC in obesity is VAT. Further studies will need to be performed to determine if this hypothesis
is correct.
The combination of low SKM and high IL-6 expression was shown above to be associated with a
significantly decreased overall survival. IL-6, an activator of STAT3, frequently elevated in RCC [31], is
known to induce tumor progression and metastasis across tumor types [43], and is sufficient to induce
skeletal muscle STAT3 activation leading to muscle wasting resulting cachexia [44,45]. Tumor-specific
antineoplastic agents have also been suspected to contribute to muscle and fat-wasting observed in
many cancers, however, few have been characterized. Sorafenib, a tyrosine kinase inhibitor often used
to treat ccRCC, is one that has been shown to independently cause muscle and fat loss, possibly via
hyperactiviation of STAT3 and ERK at the muscle [46]. Dual activation of these cachexia pathways
would be expected to cause severe cachexia resulting in shorter median survival.
Although the data presented here do not show a significant correlation between IL-6 with any
specific tissue, it does show that IL-6 expression to have an exceedingly strong negative correlation
with overall survival. With this data in mind, along with the previously established connections
between IL-6 and cachexia, care must be taken when designing chemotherapy regimens in order to
prevent possible acceleration of cachexia, especially in patients who present with low skeletal muscle
mass, resulting in poorer outcomes and decreased survival.
This study does have limitations. First, there was significant difference in age in the top three SKM
quartiles compared to the lowest quartile. It is not surprising that the lowest quartile for SKM would
be older as muscle loss is part of the aging process. The multivariate analysis showed SKM to trend
towards independent association with OS, while age showed no such evidence. In a larger cohort, the
authors expect that SKM would show an independent association with OS, while age would not.
There was also a difference in AJCC stage between quartiles for SKM and VAT and AJCC strongly
correlated with survival. The difference for SKM occurred between the first and the fourth quartiles.
OS was significantly different between the second and fourth and third and fourth SKM quartiles as
well with no difference in AJCC stage, so it can be concluded that this difference between the first
and fourth quartiles was not responsible for the difference in survival between the two groups. The
post-hoc analysis for the difference in AJCC stage in between the VAT quartiles was unable to identify
where the difference occurred, therefore, it cannot be concluded that the difference in survival between
the quartiles was due to any influence from AJCC stage.
Twenty percent (54/271) of the patients with data available in the registry were removed from
the study due to CT scans that were unable to be analyzed. This represents a significant number
and inclusion of these patients may have influenced the results. Additionally, several variables of
interest were not available in the dataset including all variables in the MSKCC-RCC risk model, type
of chemotherapy, and BMI.
Despite these limitations, the study demonstrates a clear and significant difference in OS based on
body composition and tumor cytokine expression in ccRCC. Additionally, the data were collected from
a national tumor registry, increasing the probability of a true representation of the national population
and not just a specific area of the country allowing for the results to be applied broadly.
Currently, there are limited opportunities for medical oncologists and surgical oncologists to assess
muscularity in patients with cancer. Few oncology clinics monitor body composition quantitatively.
With the advent of automated body composition analysis from diagnostic CT or MRI scans, however, the
standardized reporting of muscularity could become commonplace. Moreover, in the era of precision
medicine for oncology, many centers routinely sequence tumors, both genomic and transcriptomic.
Such molecular characterization of tumors, even for single features such as IL6, could also become as
routine as immunohistochemistry is now. These tools would permit the stratification of patient risk of
mortality, and ultimately, targeted therapy.
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4. Materials and Methods
The Cancer Imaging Archive (TCIA) [47,48] and The Cancer Genome Atlas (TCGA) https:
//www.cancer.gov/tcga were queried for patients with ccRCC. Demographic and clinical data are
available for 536 patients and RNAseq data are available for 533 patients. Abdominal computed
tomography (CT) scans adequate for analysis were available for 217 of the patients with available clinical
data and 215 of the patients with available RNAseq data. Images were analyzed for cross-sectional
area (cm2) of SKM, VAT, and SCAT at the level of the third lumbar vertebrae (L3) using Slice-O-Matic
software V4.3 (Tomovision, Montreal, Quebec, Canada) (Figure 1). Hounsfield unit thresholds were
set at −29 to +150 for SKM, −50 to −150 for VAT, and at −30 to −190 for SCAT. Two consecutive
images at L3 were assessed. The mean of the 2 images was used for statistical analysis. Total muscle
measurements included the rectus abdominus, external and internal oblique, transversus abdominus,
psoas, erector spinae, and quadratus lumborum.
The TCGA database was queried for RNAseq data for the 217 patients with analyzed CT scans.
Only 2 patients did not have RNAseq data available resulting in a total of 215 patients. A total of 20,531
total genes were identified. A total of 1,369 genes were found to be expressed in <10% of the samples
and were removed resulting in 19,162 genes for analysis.
Patients were divided into quartile for each tissue by sex. The male and female quartiles were
analyzed individually and combined by the Kaplan–Meier method to evaluate for differences in
overall survival. When a difference was present, Kaplan–Meier survival curves were created between
each quartile to identify where the difference existed. Univariate and multivariate Cox proportional
hazard models were created for each sex and the sexes combined. All hazard ratios are reported 95%
confidence intervals and p values.
Body composition and overall survival were compared with tumor gene expression of 21
cachexia-associated cytokines which included Interleukin-1 alpha (IL1a), Interleukin-1 beta (IL1b),
Interleukin-6 (IL6), Interleukin-11 (IL11), Tumor Necrosis Factor (TNF), Growth Differentiation
Factor-11 (GDF11), Growth Differentiation Factor-15 (GDF15), Myostatin (MSTN), Oncostatin M
(OSM), Chemokine C-C motif ligand 2 (CCL2), Ciliary Neurotrophic Factor (CNTF), Cardiotrophin-like
Cytokine Factor 1 (CLCF1), Cardiotrophin 1 (CTF1), Inhibin alpha (INHA), Inhibin Beta A (INHBA),
Inhbin Beta B (INHBB), Follistatin (FST), Follistatin-like 3 (FSTL3), Transforming Growth Factor Beta-1
(TGFB1), Transforming Growth Factor Beta-2 (TGFB2), and Transforming Growth Factor Beta-3 (TGFB3).
Spearman’s rank correlation with false discovery rate for multiple comparisons was performed. A rho
value >0.1 and p value < 0.05 were considered significant. Only significant associations are reported.
Continuous variables were assessed with student t-test or one-way analysis of variance (ANOVA)
when appropriate. Categorical variables were analyzed using chi-squared test and Mann–Whitney U
test. All results are reported as means with standard deviation. All statistical analyses were completed
using IBM SPSS Statistics for Windows version 23.0 (SPSS, Chicago, IL). Results were considered
significant at the p < 0.05.
5. Conclusions
Low skeletal muscle and visceral and subcutaneous adipose masses have a clear and significant
association with decreased overall survival in patients with clear cell renal carcinoma. These findings
support previous studies, agreeing that cachexia is a major cause of mortality in cancer, adding
ccRCC to the list of malignancies in which this association has been made. Additionally, a number of
tumor-derived cytokines are associated with an increased risk of all-cause mortality, perhaps most
importantly IL-6. Finally, we show, for the first time, that the combination of low skeletal muscle
mass and high IL-6 expression is an especially concerning combination that predicts early death in
patients with ccRCC. Ultimately, once the appropriate tools are available, including automated body
composition analysis and reporting of tumor transcriptomics, these factors could be considered when
designing a patient care plan and counseling ccRCC patients on prognoses.
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